1027 related articles for article (PubMed ID: 16098235)
1. Molecular and therapeutic aspects of varicella-zoster virus infection.
Quinlivan M; Breuer J
Expert Rev Mol Med; 2005 Aug; 7(15):1-24. PubMed ID: 16098235
[TBL] [Abstract][Full Text] [Related]
2. Molecular studies of Varicella zoster virus.
Quinlivan M; Breuer J
Rev Med Virol; 2006; 16(4):225-50. PubMed ID: 16791838
[TBL] [Abstract][Full Text] [Related]
3. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster.
Breuer J; Whitley R
Herpes; 2007 Sep; 14 Suppl 2():25-9. PubMed ID: 17939892
[TBL] [Abstract][Full Text] [Related]
4. Varicella-zoster virus latency in human ganglia.
Kennedy PG
Rev Med Virol; 2002; 12(5):327-34. PubMed ID: 12211045
[TBL] [Abstract][Full Text] [Related]
5. Investigations of the pathogenesis of Varicella zoster virus infection in the SCIDhu mouse model.
Arvin AM
Herpes; 2006 Nov; 13(3):75-80. PubMed ID: 17147912
[TBL] [Abstract][Full Text] [Related]
6. Immune evasion as a pathogenic mechanism of varicella zoster virus.
Abendroth A; Arvin AM
Semin Immunol; 2001 Feb; 13(1):27-39. PubMed ID: 11289797
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for varicella-zoster virus infections.
Andrei G; Snoeck R
Expert Opin Emerg Drugs; 2011 Sep; 16(3):507-35. PubMed ID: 21699441
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic understanding and control of varicella-zoster virus infection.
Asano Y
Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
10. A model of Varicella-Zoster reactivation.
Forde JE; Meeker B
Math Biosci Eng; 2010 Oct; 7(4):765-77. PubMed ID: 21077706
[TBL] [Abstract][Full Text] [Related]
11. [Reactivation of herpes zoster infection by varicella-zoster virus].
Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I; Brkić S; Bogdanović M
Med Pregl; 1999; 52(3-5):125-8. PubMed ID: 10518396
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
13. Prevention of shingles by varicella zoster virus vaccination.
Holodniy M
Expert Rev Vaccines; 2006 Aug; 5(4):431-43. PubMed ID: 16989624
[TBL] [Abstract][Full Text] [Related]
14. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine.
Diaz PS; Smith S; Hunter E; Arvin AM
J Immunol; 1989 Jan; 142(2):636-41. PubMed ID: 2536059
[TBL] [Abstract][Full Text] [Related]
15. Varicella-zoster virus infection of a human CD4-positive T-cell line.
Zerboni L; Sommer M; Ware CF; Arvin AM
Virology; 2000 May; 270(2):278-85. PubMed ID: 10792986
[TBL] [Abstract][Full Text] [Related]
16. Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment.
Balfour HH
Scand J Infect Dis Suppl; 1991; 80():69-74. PubMed ID: 1666447
[TBL] [Abstract][Full Text] [Related]
17. Key issues in varicella-zoster virus latency.
Kennedy PG
J Neurovirol; 2002 Dec; 8 Suppl 2():80-4. PubMed ID: 12491156
[TBL] [Abstract][Full Text] [Related]
18. Latency and reactivation of varicella zoster virus infections.
Dueland AN
Scand J Infect Dis Suppl; 1996; 100():46-50. PubMed ID: 9163025
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and current approaches to control of varicella-zoster virus infections.
Gershon AA; Gershon MD
Clin Microbiol Rev; 2013 Oct; 26(4):728-43. PubMed ID: 24092852
[TBL] [Abstract][Full Text] [Related]
20. Simian varicella: a model for human varicella-zoster virus infections.
Gray WL
Rev Med Virol; 2004; 14(6):363-81. PubMed ID: 15386593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
